Literature DB >> 18642634

Posttraumatic rehabilitation and one year outcome following acute traumatic brain injury (TBI): data from the well defined population based German Prospective Study 2000-2002.

K R H von Wild1.   

Abstract

Follow-up examination to review the one-year outcome of patients after craniocerebral trauma with respect to health related quality of life (QoL) and social reintegration. The data are derived from the prospective controlled, well defined population based, multiple centre study that was performed in Germany for the first time in the years 2000-2001 with emphasis on quality management (structural, process, outcome) and regarding the patient's age, physical troubles, and impaired mental-cognitive, neurobehavioral functioning. TBI severity assessment is according to the Glasgow Coma Scale (GCS) score. Early outcome after rehabilitation is assessed by the Glasgow Outcome Scale (GOS) score of patients following rehabilitation and of 63% of all TBI with the aid of follow-up examination (simplified questionnaire) after one year. Catchment areas are Hanover (industrial) and Münster (more rural) with 2,114 million inhabitants. TBI is diagnosed according to ICD 10 S-02, S-04, S-06, S-07, S-09 with at least two of the following symptoms: dizziness or vomiting; retrograde or anterograde amnesia, impaired consciousness, skull fracture, and/or focal neurological impairment. Within one year 6.783 patients (58% male) were examined in the regional hospitals after acute TBI. The regional TBI incidence regarding hospital admission was 321/100.000 TBI. 28% of patients were < 1 to 15 years, 18% > 65 years of age. GCS was only assessed in 55% of patients. They were 90.9% mild, 3.9% moderate, and 5.2% severe TBI. A total of 5.221 TBI (= 77%) was hospitalised; 1.4% of them died. Only 258 patients (= 4.9%) of the hospitalized TBI received in-hospital neurorehabilitation (73% male), 68% within one month after injury. They were 10.9% severe, 23.4% moderate, and 65.7 mild TBI. 5% were < 16 years, 25% > 65 years. One-year follow-up examinations of 4307 individuals (= 63.5% of all TBI) are discussed. A total of 883 patients (= 20.6%) reported posttraumatic troubles, one half were > 64 years. One hundred and sixty patients (= 3.8%) could manage their daily life only partly; 75 TBI (= 87.2%) following mild, 5.8% moderate, and 7% severe TBI. One hundred and sixteen patients could not at all manage their activities in training, at school, or in their jobs (N = 33 MTBI respectively 54%), 6 (= 10%) moderate, and 22 (= 36%) severe TBI. 2.8% of individuals failed when compared with their pre-traumatic situation. TBI severity, patient's age, concomitant organ lesions, and complications influence health related QoL and early social reintegration.

Entities:  

Mesh:

Year:  2008        PMID: 18642634     DOI: 10.1007/978-3-211-78205-7_9

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  11 in total

1.  Unresponsive wakefulness syndrome: a new name for the vegetative state or apallic syndrome.

Authors:  Steven Laureys; Gastone G Celesia; Francois Cohadon; Jan Lavrijsen; José León-Carrión; Walter G Sannita; Leon Sazbon; Erich Schmutzhard; Klaus R von Wild; Adam Zeman; Giuliano Dolce
Journal:  BMC Med       Date:  2010-11-01       Impact factor: 8.775

2.  Impact of aging on the immune response to traumatic brain injury (AIm:TBI) study protocol.

Authors:  Hilaire J Thompson; Frederick Rivara; Kyra J Becker; Ronald Maier; Nancy Temkin
Journal:  Inj Prev       Date:  2019-09-03       Impact factor: 2.399

3.  Alterations of connectivity patterns in functional brain networks in patients with mild traumatic brain injury: A longitudinal resting-state functional magnetic resonance imaging study.

Authors:  Maria M D'Souza; Mukesh Kumar; Ajay Choudhary; Prabhjot Kaur; Pawan Kumar; Poonam Rana; Richa Trivedi; Tarun Sekhri; Ajay K Singh
Journal:  Neuroradiol J       Date:  2020-01-28

4.  Bromocriptine for control of hyperthermia in a patient with mixed autonomic hyperactivity after neurosurgery: a case report.

Authors:  Seong Hee Kang; Min Ja Kim; Il Young Shin; Dae Won Park; Jang Wook Sohn; Young Kyung Yoon
Journal:  J Korean Med Sci       Date:  2012-07-25       Impact factor: 2.153

5.  Defining neurotrauma in administrative data using the International Classification of Diseases Tenth Revision.

Authors:  Amy Y Chen; Angela Colantonio
Journal:  Emerg Themes Epidemiol       Date:  2011-05-15

6.  Cross-sectional analysis of data from the U.S. clinical trials database reveals poor translational clinical trial effort for traumatic brain injury, compared with stroke.

Authors:  Lucia M Li; David K Menon; Tobias Janowitz
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

7.  Functional outcome following rehabilitation in chronic severe traumatic brain injury patients: A prospective study.

Authors:  Anupam Gupta; Arun B Taly
Journal:  Ann Indian Acad Neurol       Date:  2012-04       Impact factor: 1.383

8.  Specific and evolving resting-state network alterations in post-concussion syndrome following mild traumatic brain injury.

Authors:  Arnaud Messé; Sophie Caplain; Mélanie Pélégrini-Issac; Sophie Blancho; Richard Lévy; Nozar Aghakhani; Michèle Montreuil; Habib Benali; Stéphane Lehéricy
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

9.  Silent Epidemic: The Effects of Neurofeedback on Quality-of-Life.

Authors:  Rajakumari Pampa Reddy; Jamuna Rajeswaran; Indira Devi Bhagavatula; Thennarasu Kandavel
Journal:  Indian J Psychol Med       Date:  2014-01

10.  Implementing evidence-based recommended practices for the management of patients with mild traumatic brain injuries in Australian emergency care departments: study protocol for a cluster randomised controlled trial.

Authors:  Marije Bosch; Joanne E McKenzie; Duncan Mortimer; Emma J Tavender; Jill J Francis; Sue E Brennan; Jonathan C Knott; Jennie L Ponsford; Andrew Pearce; Denise A O'Connor; Jeremy M Grimshaw; Jeffrey V Rosenfeld; Russell L Gruen; Sally E Green
Journal:  Trials       Date:  2014-07-11       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.